After treatment of primary breast cancer, endocrine therapy (ET) is prescribed for patients with hormone receptor-positive cancers. Despite ET recommendations of 5 to 10 years of treatment, to the authors' knowledge there is little prospective study of its impact on cognitive function over an extended period of time. ET has known pharmacologic effects on the brain. Cognitive side effects are a concern for many women, with mixed findings reported in various studies. The current prospective longitudinal study examined the neuropsychological effects of ET over time, up to 6 years after treatment. METHODS: A total of 189 survivors of early-stage breast cancer enrolled in the study prior to initiating ET if prescribed, and were followed at 6 months (175 patients), 12 months (173 patients), and for 3 to 6 years (102 patients) with self-report and neuropsychological assessments. Using linear mixed models, the authors examined whether neuropsychological performance or impairment rates differed over time based on whether or not ET was received. RESULTS: The authors did not find any effect of ET on neuropsychological performance or impairment at any time point among survivors who received it compared with women who did not. However, those who participated in the 3-year to 6-year year visit demonstrated better executive function at baseline. CONCLUSIONS: In the current observational cohort study, no detrimental effect of ET on cognitive function was identified in survivors of early-stage breast cancer receiving treatment with ET compared with those who were not. Cancer 2019;125:681-689.
INTRODUCTION
Endocrine therapy (ET) is widely used in the adjuvant treatment of patients with breast cancer to reduce disease recurrence and improve survival, with recommended treatment lasting up to 5 to 10 years. 1 These treatments systematically interfere with the action of estrogen in the body and brain, including possible neurocognitive dysfunction. 2 To the best of our knowledge, our team was among the first to report worse neuropsychological functioning in survivors of breast cancer (BCS) 2 to 5 years after diagnosis that was related to adjuvant tamoxifen treatment. 3 Several cross-sectional and longitudinal studies have since reported mixed results. [4] [5] [6] [7] [8] [9] [10] However, sample sizes across studies tend to be small and longitudinal studies often have limited durations of follow-up. There remains substantial uncertainty regarding the cognitive effects of ET given its protracted use. 2 The Mind Body Study (MBS) was a prospective longitudinal study specifically designed to evaluate the effects of ET on neuropsychological function in BCS. BCS were evaluated within 3 months of completing primary cancer treatment but before initiating ET if it was indicated, followed by 6-month and 12-month follow-up assessments. Follow-up of the MBS cohort was extended beyond the first year, including an additional in-person assessment visit that took place approximately 3 to 6 years after their baseline evaluation. We previously reported finding worse cognitive symptoms at 6 months among those patients receiving ET, associated with diminished improvement in psychomotor speed. 11 In an analysis of self-reported symptoms over the first year of the study, we also found worse cognitive symptoms among participants receiving ET compared with those not receiving this treatment at 6 and 12 months, 12 but have not yet reported neuropsychological outcomes. The current study is a report of the longitudinal
Cancer March 1, 2019 neuropsychological data across all 4 time points, and to the best of our knowledge is the longest prospective study of the cognitive effects of ET to date. Given our prior findings, we hypothesized that BCS receiving ET would demonstrate diminished neuropsychological functioning over time compared with those not receiving ET.
MATERIALS AND METHODS
The MBS methods are described in detail elsewhere, and will be summarized briefly. [11] [12] [13] Between 2007 and 2011, patients newly diagnosed with early-stage breast cancer were recruited through clinical oncology practices and rapid case ascertainment using the Los Angeles County Surveillance, Epidemiology, and End Results program registry with collaborating physicians and hospitals. The baseline visit occurred within 3 months of the completion of primary cancer treatment with surgery, radiotherapy, and/or chemotherapy but before the initiation of ET if prescribed. Identical follow-up visits occurred at 6 months and 12 months after baseline. At each study visit, we administered a questionnaire battery, collected blood for genetic and inflammatory markers, and administered a comprehensive neuropsychological battery. At the end of the 12-month visit, we reconsented all active participants for longer-term follow-up that included annual questionnaires and a final in-person neuropsychological assessment. This final visit occurred approximately 3 to 6 years after baseline (the fourth and final time point in the current analysis). Figure 1 shows a schematic of the study in-person visits. Inclusion criteria were age 21 to 65 years; a diagnosis of stage 0, I, II, or IIIA breast cancer (TNM Staging System); primary breast cancer treatments completed within the past 3 months; patient being available for 12-month follow-up; and English proficiency. We excluded participants who had a history of a prior cancer diagnosis or receipt of chemotherapy, whole-brain irradiation or surgery, a neurological disease (eg, seizures or epilepsy, dementia, or multiple sclerosis), head trauma with prolonged loss of consciousness, a current or past psychotic spectrum disorder or current uncontrolled major affective disorder, an active autoimmune disorder, insulin-dependent diabetes, uncontrolled allergic condition or asthma, chronic steroid use, and hormone therapy (estrogen, progestin compounds) other than vaginal estrogen. The current study was approved by the institutional review board at the University of California at Los Angeles and all participants provided written informed consent.
Measures
We obtained clinical information through medical record review. Participants completed self-report questionnaires and a standard neuropsychological battery, as presented in Table 1 14-24 by domain. Participants' neuropsychological test scores were transformed into z scores using appropriate published normative data, and then averaged into cognitive domain scores. We examined the frequency of test scores that were <-1.5 or <-2 z score based on standard clinical practice, and characterized impairment based on International Cognition and Cancer Task Force guidelines (ICCTF). 25 The battery changed slightly at the final 3-year to 6-year visit (as described in Table 1 ), but domains were comparable and treated as equivalent in analyses to capitalize on this unique and valuable long-term assessment.
Statistical Analyses
Student t tests and chi-square tests were used to examine group differences regarding demographic and clinical variables. We divided participants into 2 groups based on whether or not they initiated ET shortly after primary cancer treatment (ie, ET yes/ET no). The ET factor in models is time-invariant, akin to an intent-to-treat approach, the rationale being that our focus was the effects of any ET exposure initiated after primary treatment. The Cancer March 1, 2019 majority of women planning to initiate ET did so within the first few months after the baseline assessment and the majority continued to receive some ET without interruption. However, not all women consistently took their medications or took the same type of ET, and therefore we present a breakdown of ET use patterns. To test group differences among cognitive domains over time, we conducted linear mixed effect models for repeated measures, which accommodate missing data among participants. We examined various covariance structures and diagonal was consistently superior. 26 All models included random intercepts; fixed effects included time, age, intelligence quotient (IQ), chemotherapy exposure, Beck Depression Inventory-second edition (BDI-II), and race, as well as the terms of interest, namely the main effects of ET and ET multiplied by time. We modelled time as a categorical factor (ie, baseline, 6 month, 12 month, and 3-6 years). We examined whether -2 restricted log likelihood criteria improved with the addition of the 2 ET terms. We also tested ET group differences in neuropsychological impairment variables using analysis of covariance and binary logistic regression at each time point; these analyses controlled for age, IQ, race, BDI-II, and chemotherapy exposure. We used SPSS statistical software (version 24; IBM Corporation, Armonk, New York), and statistical significance was set at P = .05.
RESULTS
A total of 191 BCS were enrolled in the MBS study. The data for 2 patients were excluded based on incomplete testing and English being a second language. Five participants missed their 6-month evaluation, and 5 participants dropped out after their 6-month evaluation. Two participants were missing neuropsychological data at 12 months. The resulting analyzable sample size was 189 participants at baseline (63 participants in the ET no group and 126 participants in the ET yes group [ie, prescribed subsequently]), 175 participants at 6 months (49 participants in the ET no group and 126 participants in the ET yes group), 173 participants at 12 months (52 participants in the ET no group and 121 participants in the ET yes group), and 102 participants at 3 to 6 years (28 participants in the ET no group and 74 participants in the ET yes group). Table 2 presents the baseline demographic and clinical characteristics of the total sample and by ET group. Participants in the 2 groups were comparable across the majority of demographic and clinical variables, with expected differences of a higher stage of disease and higher frequency of radiotherapy in women prescribed ET.
Of the original study sample, 102 women (53%) consented to undergo neuropsychological evaluation at the longer-term follow-up; participants were an average of 4.3 years (±0.66 years) from baseline (range, 3-6 years), and there was no difference noted with regard to the follow-up period between the ET groups (P = .24). The rest of the initial sample either declined or were not reachable. To examine participation bias, we compared baseline differences between those who consented to return for neuropsychological testing and those who did not. We found that those who consented to the add-on follow-up were comparable to those who did not based on age (P = .27), IQ (P = .74), education (P = .93), chemotherapy (P = .56), and BDI-II scores (P = .34). However, we did find that those who consented to the add-on follow-up demonstrated higher executive function scores at baseline compared with those who did not (P = .02), but comparable performance in other domains. We did not observe any differences in participation in the add-on follow-up based on ET use or type of ET medication.
ET Use
Of those participants who returned for a follow-up visit, 126 had initiated ET and 49 had not, which defined the grouping variable used in the models. The majority of those initiating ET (97%) began treatment after their baseline evaluation and before their 6-month evaluation, The WAIS and WMS tests used at the baseline, 6-month, and 12-month visits were the third edition and fourth edition tests were used at the 3-year to 6-year visit, which are highly correlated with the third edition tests. The Stroop test was not administered at the 3-year to 6-year visit. It also should be noted that 20 participants were missing WAIS-III Digit Span data at baseline.
Cancer March 1, 2019 and 4 participants started after their 6-month but before their 12-month evaluation. Two participants initiated ET after their 12-month evaluation but before 3 to 6 years (one initiated treatment with an aromatase inhibitor [AI] and one with tamoxifen), whom we grouped as part of the ET no group because our analyses addressed ET exposure right after primary cancer treatment. Because this was a naturalistic study, several participants did go on and off treatment or switched treatments over the course of the study. At 6 months, 61 participants were receiving tamoxifen, 57 participants were receiving an AI, and 4 participants were receiving ovarian suppression. The majority of those who initiated treatment with an AI were postmenopausal (93%); the majority who initiated treatment with tamoxifen or ovarian suppression were premenopausal (77% and 100%, respectively). At 12 months, 54 participants continued to receive tamoxifen, 52 continued treatment with an AI, and all 4 participants continued ovarian suppression; others newly started treatment (4 participants), switched medications (4 participants), or stopped altogether (3 participants). Of those receiving ET who returned for the 3-year to 6-year visit, the majority remained on 1 agent (63 participants; 85%), but some switched agents (17 participants). A few went on and off ET over time points (11 participants; 15%) . At 3 to 6 years, 15 of 25 participants who were taking tamoxifen and 30 of 46 participants who were taking an AI had been consistently taking the same medication type at prior visits; the one individual receiving ovarian suppression had switched from tamoxifen.
Neuropsychological Performance by ET Group
We examined neuropsychological performance over time based on ET group using mixed effects models that included the main effects of age, IQ, BDI-II, race, and chemotherapy exposure as well as random intercepts. The F-tests for the fixed effects of time and ET and the ET multiplied by time term are presented in Table 3 . Figure 2 displays graphs of each domain by ET group across all time points (estimates were derived from linear mixed effects models). As shown in Table 3 and Figure 2 , we did not observe a significant main effect of ET or a significant interaction of ET multiplied by time in any domain. Significant main effects of time generally portray improvement from baseline in the first year in the majority of domains.
Impairment
We also examined rates of impairment on neuropsychological tests using standard cutoff values and impairment based on ICCTF criteria at each time point by ET use, controlling for age, IQ, BDI-II, race, and chemotherapy exposure. As shown in Table 4 , we did not detect any Cancer March 1, 2019 significant differences in the number of impaired tests or number of impaired participants by ICCTF criteria based on ET group at any time point.
DISCUSSION
The current prospective, longitudinal study examined whether ET affected neuropsychological performance in a well-characterized sample of BCS. We were able to extend our original study from a 1-year follow-up period to include a neuropsychological assessment 3 to 6 years after baseline, making it to our knowledge the longest longitudinal cognitive study of ET to date. Based on our previous findings, we hypothesized that those receiving ET would demonstrate diminished neuropsychological performance compared with those not receiving ET in models accounting for age, IQ, race, depression, and chemotherapy exposure. 3, 11 Contrary to our prediction, we observed no differences in any neuropsychological domain based on ET use in the first year after the completion of primary cancer treatment or at a subsequent follow-up 3 to 6 years later. Across the majority of domains, both groups demonstrated improvement at similar rates in the first year, followed by a return to baseline levels at the later 3-year to 6-year follow-up. We also examined neuropsychological impairment in a few ways, again failing to find group differences with regard to the rate of neuropsychological impairment over time. For the sake of simplifying analyses and interpretation, we used a time-invariant variable for ET based on whether the participant initiated a medication shortly after completing primary treatment (ie, not necessarily recent use although most were). We also conducted sensitivity analyses using a time-varying grouping variable (data not shown) (ie, group membership reflected recent ET use), and observed similar results across domains. Although the side effects of ET have been a concern for patients and providers, 4,28 these negative neuropsychological test results contribute to reassurances regarding the safety of these medications.
Although reassuring, the current study findings are somewhat surprising and require measured interpretation. The role of endogenous estrogen in the brain is complex and believed to be neuroprotective. 29 ET agents cross the blood-brain barrier and are known to interfere with the action of estrogen in the brain based on preclinical studies. 2 Several prior studies have suggested that ET leads to adverse cognitive outcomes, including work from our laboratory. 3, 6, 8, 10, 11, [30] [31] [32] Some studies have suggested that tamoxifen may have cognitive effects, 4, 6, 33 whereas other studies have found evidence for AIs 30 or both. 10 Cognitive data from well-controlled randomized clinical trials demonstrate a similarly mixed picture, with some suggestion that tamoxifen in particular leads to adverse cognitive effects 6,32,34 but not AIs. 35 However, to the best of our knowledge, the current study is one of the largest and longest to date and joins other cross-sectional and longitudinal studies that have similarly failed to find any cognitive effects of ET within the first year after treatment. 36, 37 Likewise, results from a recent meta-analysis did not yield compelling evidence that ET has significant cognitive effects, finding only a cross-sectional effect on verbal memory and failing to find a longitudinal effect in any domain. 38 The majority of studies regarding the cognitive effects of ET are complicated by methodological issues. First, most focus on postmenopausal women or a mixed sample of both premenopausal and postmenopausal women, as in the current study. Our early report of worse cognition in premenopausal women being treated with tamoxifen then was joined by only a few other studies. 3, 5, 39 This methodological issue may be obscuring effects: menopausal status itself is associated with cognitive changes 40 in addition to influencing the type of ET agent recommended, leading to different alterations in estrogen-related functioning in the brain. 2 Furthermore, chemotherapy c80 (63%)an induce early menopause, 36 and may have other unknown Abbreviations: ET, endocrine therapy (no/yes); time, baseline, 6-month, 12-month, and 3-year to 6-year visits (categorical, with baseline as the referent).
The fixed effects included in the models were age, intelligence quotient, chemotherapy exposure, race, and Beck Depression Inventory-second edition and all models included a random intercept.
Cancer March 1, 2019 additive effects. Because many prior studies have excluded chemotherapy, 2 it remains unknown whether its neurotoxic effects interact with ET. Furthermore, the role of prior hormone replacement therapy is poorly understood. The current study was powered and designed for broader questions than these, when there was scarce evidence in this area. Thus, future nuanced investigations are needed to better rule out or isolate medication effects, and to determine whether we are missing vulnerable subgroups.
Second, as we have previously argued, the weaknesses of traditional neuropsychological tests may undercut efforts to detect subtle cognitive effects in patients with cancer. 41 Neuropsychological tests are subject to practice effects (ie, "benefit" from prior test exposure 42 ), thus complicating longitudinal observations. The pattern of improvement observed in the current study may represent some early recovery from the effects of primary cancer treatment, but it appears likely that the initial Cancer March 1, 2019 improvement rather was due to practice effects, with later diminished practice effects observed after a years-long break from testing. Future studies can better account for practice effects using methodologies not available in the current study (eg, a control group). Recently, others have similarly pointed out that "noise" in repeated neuropsychological assessments precludes adequate sensitivity to subtle effects in cancer samples. 43 Other methods may be more useful, such as considering patients' self-report of cognitive changes 11 and promising but understudied neuroimaging approaches. 44, 45 Our prior reports from this sample have revealed worse self-reported cognitive symptoms at 6 months among those receiving ET, 12, 13 and we next will systematically examine self-report measures across all time points.
With regard to study limitations, the current study sample was predominantly white and highly educated. Studies of the cognitive effects of ET, particularly in diverse samples, are needed because effects may not be uniform. We do not have a precancer treatment assessment, which is important for isolating effects and recovery from other treatments. The current study was naturalistic and treatment regimens followed clinical recommendations; therefore, women who experienced more severe side effects may have opted to discontinue ET or switched to a different medication, potentially diminishing observable effects. It is important to note that the initial study retention was good, but we detected participation bias among those who consented to return for the add-on follow-up several years later, with better baseline executive function noted among those who returned. Other longitudinal studies of the cognitive effects of ET similarly have found that those who dropped out were more cognitively vulnerable, 6 or more likely to be receiving ET. 46 In the cognitive aging field, it is well known that attrition often is observed disproportionately in those with cognitive compromise. 47 It is interesting to note that the recent meta-analysis only found a cognitive effect of ET in cross-sectional studies, not longitudinal ones. 38 Longitudinal studies of ET such as the current study may be missing important data from vulnerable women who choose to avoid lengthy and challenging cognitive assessments. In addition, the final time point captures a wide timeframe from baseline (ie, 3-6 years), reflecting the range of the initial study enrollment period, and future studies are needed to more carefully establish cognitive risk over time.
The results of the current study suggest that there are no significant neuropsychological differences in performance or impairment rates between BCS who do or do not initiate ET after primary cancer treatment, even years after starting these medications. This provides some reassurance to the many thousands of women receiving these medications who may be concerned about cognitive effects. However, within the context of a mixed literature and important methodological considerations, the results presented herein highlight the need for more nuanced study of these 
